ATE277186T1 - Zusammensetzung von transdominanten varianten von virus- proteinen zur antiviralen wirkung - Google Patents

Zusammensetzung von transdominanten varianten von virus- proteinen zur antiviralen wirkung

Info

Publication number
ATE277186T1
ATE277186T1 AT95903829T AT95903829T ATE277186T1 AT E277186 T1 ATE277186 T1 AT E277186T1 AT 95903829 T AT95903829 T AT 95903829T AT 95903829 T AT95903829 T AT 95903829T AT E277186 T1 ATE277186 T1 AT E277186T1
Authority
AT
Austria
Prior art keywords
composition
variants
antiviral effect
virus proteins
transdominant variants
Prior art date
Application number
AT95903829T
Other languages
English (en)
Inventor
Majid Mehtali
Tania Guss
Original Assignee
Transgene Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transgene Sa filed Critical Transgene Sa
Application granted granted Critical
Publication of ATE277186T1 publication Critical patent/ATE277186T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/60—Vector systems having a special element relevant for transcription from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT95903829T 1993-12-13 1994-12-13 Zusammensetzung von transdominanten varianten von virus- proteinen zur antiviralen wirkung ATE277186T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9314914A FR2713651B1 (fr) 1993-12-13 1993-12-13 Nouvelle composition pour un effet antiviral.
PCT/FR1994/001457 WO1995016780A1 (fr) 1993-12-13 1994-12-13 Composition de variants transdominants de proteines virales pour un effet antiviral

Publications (1)

Publication Number Publication Date
ATE277186T1 true ATE277186T1 (de) 2004-10-15

Family

ID=9453843

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95903829T ATE277186T1 (de) 1993-12-13 1994-12-13 Zusammensetzung von transdominanten varianten von virus- proteinen zur antiviralen wirkung

Country Status (8)

Country Link
EP (1) EP0682708B9 (de)
AT (1) ATE277186T1 (de)
AU (1) AU685560B2 (de)
CA (1) CA2155844A1 (de)
DE (1) DE69434019T2 (de)
ES (1) ES2229232T3 (de)
FR (1) FR2713651B1 (de)
WO (1) WO1995016780A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2349760C (en) 1998-11-02 2012-02-21 University Of Saskatchewan Bovine cells expressing adeno virus essential functions for propagation of recombinant adenoviral vectors
FR2982277B1 (fr) 2011-11-08 2015-08-21 Agronomique Inst Nat Rech Cassette d'expression inductible et ses utilisations

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL94482A (en) * 1989-05-25 2003-09-17 Univ Duke Transdominant repressor mutant of retroviral protein, dna encoding the protein and process for their preparation and use thereof

Also Published As

Publication number Publication date
CA2155844A1 (fr) 1995-06-22
AU1275095A (en) 1995-07-03
WO1995016780A1 (fr) 1995-06-22
FR2713651B1 (fr) 1996-04-19
AU685560B2 (en) 1998-01-22
EP0682708A1 (de) 1995-11-22
DE69434019D1 (de) 2004-10-28
ES2229232T3 (es) 2005-04-16
EP0682708B1 (de) 2004-09-22
EP0682708B9 (de) 2005-03-02
FR2713651A1 (fr) 1995-06-16
DE69434019T2 (de) 2005-09-15

Similar Documents

Publication Publication Date Title
EA199901031A1 (ru) Производные бензимидазола
CZ63995A3 (en) Virus vectors and their use in gene therapy
BR0009866A (pt) Método de inibição de infecção viral, uso de uma proteìna de ligação de antìgeno monovalente, produto alimentìcio, composição farmacêutica ou cosmética, proteìna de ligação de antìgeno monovalente, sequência de nucleotìdeos, vetor de expressão, célula hospedeira, e, métodos de seleção e de indentificação de uma proteìna de ligação de antìgeno
BRPI0113286B8 (pt) pirazóis substituídos e composição farmacêutica compreendendo os mesmos.
ATE303378T1 (de) Benzothiepinen mit wirkung als inhibitoren des ileumgallensäuretransports und der taurocholate- aufnahme
DE69820450D1 (de) Chimäre vektoren, die die verpackungsregion eines phagengenoms und einen teil des genoms eines eukaryontischen virus enthalten
ATE298741T1 (de) Polyaromatische verbindungen zur behandlung von herpes-infektionen
ATE165345T1 (de) Sulfonsaeurederivate zur behandlung von viruserkrankungen
ITFI930083A1 (it) Composti pirrol-amidinici, processi di preparazione e composizioni farmaceutiche che li contengono.
CA2051288A1 (en) Viral targeted destruction of neoplastic cells
KR970702919A (ko) 재조합형의 인간면역부전바이러스 담체 및 그 제조방법(Recombinant Human Immunodeficiency Virus Vector and Process for Producing the same)
DE69420229D1 (de) Pharmazeutische Zusammensetzung zur Behandlung von AIDS
EA199800526A1 (ru) Производные бензимидазола и их применение для лечения вирусных инфекций
ES2169037T3 (es) Conjugados polietilenglicol-hirudina, su procedimiento de preparacion y su empleo para el tratamiento de las trombosis.
BR9605046B1 (pt) compostos n-(pirimidinl)-benzenossulfonamida e preparação farmacêutica contendo as mesmas.
DE69434019D1 (de) Zusammensetzung von transdominanten varianten von virus- proteinen zur antiviralen wirkung
ATE310828T1 (de) Implantat und vektor zur behandlung von erworbenen krankheiten
BG102404A (en) The application of flupirtin for the prevention and treatment of diseases related to impairement of the haematopoeic cellular system
DK0656889T3 (da) 9-chlorprostaglandinestere og -amider og deres anvendelse ved fremstilling af lægemidler
DK0614910T3 (da) Renset form af streptograminer, dens fremstilling og farmaceutiske præparater indeholdende denne form
NO945031L (no) Anvendelse av en hymenopteragift til fremstilling av et medikament for behandling av DNA-virusinfeksjoner
IL99543A0 (en) Oligonucleotides,pharmaceutical compositions containing the same and methods for detection of herpes virus utilizing the same
AU2190288A (en) Vector for the expression of proteins of the HIV-2 virus, one of the casual agents of AIDS, cell culture infected or transformed by this vector, proteins obtained, vaccine and antibodies obtained
FI965114A0 (fi) Farmaseuttinen koostumus virusinfektioiden sekä valinnaisesti tulehdusten estoon ja (tai) hoitoon sekä niiden hoitomenetelmä
FI960839A (fi) Uusia tripeptidejä, jotka ovat käyttökelpoisia immuuni- ja CNS-terapiassa

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties